| scholarly article | Q13442814 |
| P2093 | author name string | Jane Apperley | |
| Dragana Milojkovic | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| imatinib | Q177094 | ||
| chronic myeloid leukemia | Q729735 | ||
| P304 | page(s) | 7519-7527 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. | |
| P478 | volume | 15 |
| Q38253243 | ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis |
| Q37870181 | Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients |
| Q38285703 | Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents |
| Q92967177 | B lymphocytes protect islet β cells in diabetes prone NOD mice treated with imatinib |
| Q31153995 | BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2 |
| Q37322437 | Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target |
| Q49315568 | Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights |
| Q44337365 | Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia. |
| Q35640320 | Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. |
| Q38363058 | Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors |
| Q34408156 | Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity |
| Q37793481 | Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia |
| Q27851628 | Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling |
| Q38778888 | Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells |
| Q36245193 | Drug repositioning for personalized medicine. |
| Q48243283 | Dual gene activation and knockout screen reveals directional dependencies in genetic networks |
| Q26775622 | Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review |
| Q59329233 | Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium |
| Q94521558 | Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors |
| Q35409569 | Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia |
| Q42265763 | Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition |
| Q42110946 | HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells |
| Q58449044 | Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors |
| Q28394296 | Identification of novel drugs to target dormant micrometastases |
| Q57272446 | Identifying Actionable Targets in Cancer Patients |
| Q53670654 | Imatinib resistance in chronic myeloid leukemia due to a rare mutation. |
| Q30235979 | Implementing Genome-Driven Oncology |
| Q48189225 | Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin. |
| Q91900245 | Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments |
| Q37422287 | Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcome |
| Q90566549 | Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML |
| Q26766299 | Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment |
| Q39411920 | Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors |
| Q49833785 | Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia |
| Q38007869 | Mechanisms of acquired resistance to ERK1/2 pathway inhibitors |
| Q47117554 | Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients |
| Q36184500 | Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase |
| Q37696776 | Molecular techniques for the personalised management of patients with chronic myeloid leukaemia |
| Q90649930 | Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension |
| Q39114006 | Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks. |
| Q38392667 | Natural course and biology of CML. |
| Q26745669 | New Developments in Chronic Myeloid Leukemia: Implications for Therapy |
| Q39779762 | Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia |
| Q37645231 | Non-small cell lung cancer: the era of targeted therapy |
| Q93018937 | Novel analytical methods to interpret large sequencing data from small sample sizes |
| Q64263411 | Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients |
| Q41370892 | Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway |
| Q37781050 | Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development |
| Q58572255 | Precursor B cell lymphoid blast crisis of chronic myeloid leukemia with novel chromosomal abnormalities: A case report |
| Q37886009 | Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors |
| Q38322277 | RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loop |
| Q37208829 | Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia |
| Q28537891 | Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks |
| Q41892312 | Report of chronic myeloid leukemia in chronic phase from Omega Hospital and Indo-American Centre, Hyderabad, 2004-2010 |
| Q36318226 | Resistance to Trastuzumab in Breast Cancer. |
| Q27028181 | Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options |
| Q26738514 | Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned |
| Q33911230 | SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. |
| Q90292648 | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer |
| Q35092057 | Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cells |
| Q36331689 | Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar |
| Q28383446 | Suppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell "dormancy" |
| Q38830941 | Targeting c-kit receptor in neuroblastomas and colorectal cancers using stem cell factor (SCF)-based recombinant bacterial toxins. |
| Q26765205 | Targeting dormant micrometastases: rationale, evidence to date and clinical implications |
| Q26766341 | Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy |
| Q38191794 | Targeting tumour-supportive cellular machineries in anticancer drug development |
| Q37896606 | The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose |
| Q94544586 | The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib |
| Q37814411 | The expanding role of nilotinib in chronic myeloid leukemia |
| Q37593435 | Therapy of chronic myeloid leukemia: twilight of the imatinib era? |
| Q38797683 | Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. |
| Q39301436 | Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance |
| Q37853578 | Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? |
| Q48263612 | Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. |
| Q38839647 | WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene |
| Q38507706 | Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma? |
| Q48166615 | p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib |
Search more.